Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30954006 | 1.00 | NR1H2 (0.41) | NR1H2PIK3R1PIK3CAMAPTPIK3CD | |
| SCHEMBL27458692 | 0.85 | MAPT (0.41) | NR1H2PIK3R1PIK3CAMAPTPIK3CD | |
| SCHEMBL27458695 | 0.84 | MAPT (0.42) | NR1H2MAPTCYP11B2ESR2 | |
| SCHEMBL30513283 | 0.78 | CYP11B2 (0.41) | NR1H2MAPTCYP11B2ESR2 | |
| SCHEMBL22803887 | 0.77 | NR1H2 (0.54) | NR1H2PIK3R1PIK3CAMAPTESR2 | |
| SCHEMBL18053895 | 0.76 | NR1H2 (0.44) | NR1H2MAPTCYP11B2ESR2 | |
| SCHEMBL14380649 | 0.76 | ESR2 (0.44) | NR1H2MAPTESR2 | |
| SCHEMBL26640804 | 0.75 | NR1H2 (0.41) | NR1H2PIK3R1PIK3CAMAPT | |
| SCHEMBL10053887 | 0.75 | CYP11B2 (0.45) | NR1H2MAPTCYP11B2ESR2 | |
| SCHEMBL3530060 | 0.74 | MAPT (0.65) | NR1H2MAPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024137984-A1 | INHIBITORS OF KIF18A AND USES THEREOF | ACCENT THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |